Amino acid transport is an attractive target for oncologic imaging. Despite a high demand of
cancer cells for cationic
amino acids, their potential as PET probes remains unexplored.
Arginine, in particular, is involved in a number of biosynthetic pathways that significantly influence
carcinogenesis and
tumor biology. Cationic
amino acids are transported by several cationic transport systems including, ATB(0,+) (SLC6A14), which is upregulated in certain human
cancers including cervical, colorectal and
estrogen receptor-positive
breast cancer. In this work, we report the synthesis and preliminary
biological evaluation of a new cationic analog of the clinically used PET
tumor imaging agent O-(2-[(18)F]fluroethyl)-
L-tyrosine ([(
18)F]FET), namely O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET). Reference compound and precursor were prepared by multi-step approaches. Radiosynthesis was achieved by no-carrier-added nucleophilic [(18)F]fluorination in 16-20% decay-corrected yields with radiochemical purity >99%. The new tracer showed good stability in vitro and in vivo. Cell uptake assays demonstrated that FEMAET and [(18)F]FEMAET accumulate in
prostate cancer (PC-3) and
small cell lung cancer cells (NCI-H69), with an energy-dependent mechanism. Small animal PET imaging with NCI-H69 xenograft-bearing mice revealed good
tumor visualization comparable to [(
18)F]FET and low brain uptake, indicating negligible transport across the blood-brain barrier. In conclusion, the non-natural cationic
amino acid PET probe [(18)F]FEMAET accumulates in
cancer cells in vitro and in vivo with possible involvement of ATB(0,+).